Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib

Affiliations

¹ Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital, Paris, France.
² Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debré Hospital, University Hospital, Reims, France.

Comment

Yves Allenbach et al. Brain. 2018.

. 2018 Nov 1;141(11):e81.

doi: 10.1093/brain/awy256.

¹ Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital, Paris, France.
² Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debré Hospital, University Hospital, Reims, France.

No abstract available

Comment on

JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.
Ladislau L, Suárez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, Rodero MP, Hathazi D, Duffy D, Bondet V, Preusse C, Bienvenu B, Rozenberg F, Roos A, Benjamim CF, Gallardo E, Illa I, Mouly V, Stenzel W, Butler-Browne G, Benveniste O, Allenbach Y. Ladislau L, et al. Brain. 2018 Jun 1;141(6):1609-1621. doi: 10.1093/brain/awy105. Brain. 2018. PMID: 29741608
A child with severe juvenile dermatomyositis treated with ruxolitinib.
Aeschlimann FA, Frémond ML, Duffy D, Rice GI, Charuel JL, Bondet V, Saire E, Neven B, Bodemer C, Balu L, Gitiaux C, Crow YJ, Bader-Meunier B. Aeschlimann FA, et al. Brain. 2018 Nov 1;141(11):e80. doi: 10.1093/brain/awy255. Brain. 2018. PMID: 30335130 No abstract available.